CClinicalTrials.gg
CompletedNCT03093038RSA-DELTA-TTUpdated Oct 13, 2021

Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study.

An interventional study of H-MAX stem & Delta-TT cup + polyethylene and H-MAX stem & Delta-TT cup + ceramic in Osteoarthrosis, sponsored by JointResearch. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by JointResearch · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2014, registered Dec 2014).
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this study is to study the stability of the Delta-TT cup with polyethylene insert and the Delta-TT cup with ceramic insert both combined with the H-MAX femoral stem by means of RSA to assess whether the differences in stiffness of the cup will have an influence on incorporation and mechanical stability.

It is hypothesized that there will be more micromotion on the short-term (\<2 years) in the patients with the ceramic insert because of the higher stiffness, however, all components will be considered stable on the short and long-term.

Read the detailed description

Rationale: Roentgen Stereophotogrammetric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to inserted tantalum markers in the surrounding bone. Using RSA, long-term predictions of prosthetic loosening can be made based on a two years follow-up. Therefore, it is recommended to analyse all (new) prosthetic components by means of RSA.

Objective: The goal of this study is to study in a randomised trial the stability of the Delta-TT cup with polyethylene insert and the Delta-TT cup with ceramic insert both combined with the H-MAX femoral stem by means of RSA to assess whether the differences in stiffness of the cup will have an influence on incorporation and mechanical stability. It is hypothesized that there will be more micromotion on the short-term (\<2 years) in the patients with the ceramic insert because of the higher stiffness, however, all components will be considered stable on the short and long-term. Secondary goal is to compare the stability of the C2 femoral stem, to the H-MAX femoral stem as well as to compare it to relevant migration results of similar stems from the literature. These RSA results will contribute to knowledge about the early stability and long-term prosthetic loosening of these cementless stems.

02

Conditions studied

  • Osteoarthrosis

Browse trials for

03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 70 is close to the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

JointResearch is the lead sponsor of 13 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients scheduled to undergo primary total hip replacement.
  • Patient is able to understand the meaning of the study and is willing to sign the ethical committee approved, study-specific Informed Patient Consent Form.
  • Ability and willingness to follow instructions and to return for follow-up evaluations.
  • The subject is a male or non-pregnant female between 18 and 75 years of age.

Exclusion criteria

Exclusion Criteria:

  • The subject is morbidly obese, defined as Body Mass Index (BMI) of > 40.
  • The subject will be operated bilaterally.
  • Patients having a deformity or disease located in other joints than the hip that needs surgery and is limiting their ability to walk.
  • The subject has an active or suspected latent infection in or about the hip joint.
  • The subject has a neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.
  • The subject has a systemic or metabolic disorder leading to progressive bone deterioration.
  • The subject's bone stock is compromised by disease or infection which cannot provide adequate support and/or fixation to the prosthesis.
  • Female patients planning a pregnancy during the course of the study.
  • The patient is unable or unwilling to sign the Informed Consent specific to this study.
  • Subject deemed unsuitable for participation in the study based on the investigator's judgement.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    H-MAX stem & Delta-TT cup + polyethylene

    H-MAX femoral stem and the Delta-TT cup with polyethylene insert

    Device: H-MAX stem & Delta-TT cup + polyethylene

  • Experimental
    H-MAX stem & Delta-TT cup + ceramic

    H-MAX femoral stem and the Delta-TT cup with ceramic insert

    Device: H-MAX stem & Delta-TT cup + ceramic

  • Experimental
    C2 stem & Delta-TT cup + ceramic

    C2 femoral stem and the Delta-TT cup with ceramic insert

    Device: C2 stem & Delta-TT cup + ceramic

Interventions

  • DeviceH-MAX stem & Delta-TT cup + polyethylene

    H-MAX femoral stem \& Delta-TT cup with a polyethylene insert

  • DeviceH-MAX stem & Delta-TT cup + ceramic

    H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert

  • DeviceC2 stem & Delta-TT cup + ceramic

    C2 femoral stem Delta Delta-TT cup with a Ceramic insert

06

What researchers measure

Primary outcomes

  1. Change from Baseline in stability

    Stability will be assessed with Roentgen Stereophotogrammetric Analysis (RSA). RSA will be used to determine the micromotion of the femur and cup components with respect to the bone.The RSA data of the components will be described in terms of translational and rotational movements.

    Time frame: 2 years

Secondary outcomes

  1. Change from Baseline in Quality of Life

    Quality of Life (QoL) will be assessed with the questionaire EuroQoL 5D (EQ- 5D)

    Time frame: 2 years

  2. Change from Baseline in Quality of Life

    Quality of Life (QoL) will be assessed with the questionaire EuroQoL 5D (EQ- 5D)

    Time frame: 5 years

  3. Change from Baseline in Physical Function

    Physical Function will be assessed with the Hip disability and Osteoarthritis Outcome Score - Physical Function Short Form (HOOS-PS)

    Time frame: 2 years

  4. Change from Baseline in Physical Function

    Physical Function will be assessed with the Hip disability and Osteoarthritis Outcome Score - Physical Function Short Form (HOOS-PS)

    Time frame: 5 years

  5. Change from Baseline in Physical Function and Pain

    Physical Function will be assessed with the Oxford Hip Score (OHS)

    Time frame: 2 years

  6. Change from Baseline in Physical Function and Pain

    Physical Function will be assessed with the Oxford Hip Score (OHS)

    Time frame: 5 years

  7. Change from Baseline in Pain

    Pain will be assessed with a Numeric Rating Scale (NRS)

    Time frame: 2 years

  8. Change from Baseline in Pain

    Pain will be assessed with a Numeric Rating Scale (NRS)

    Time frame: 5 years

07

Study locations

1 site
  • Onze Lieve Vrouwe Gasthuis
    Amsterdam, Noord Holland 1090 HM, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03093038
Lead sponsor
JointResearch
Responsible party
Sponsor
First posted
Mar 28, 2017
Start date
May 2014
Primary completion
Feb 2018
Completion
May 2021
Last update
Oct 13, 2021

Study contacts

Rudolf W Poolman, MD PhD
principal investigator · Onze Lieve Vrouwe Gasthuis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion